Trevi Therapeutics to Participate in Upcoming September Events

Rhea-AI Summary

Trevi Therapeutics to attend key events in September

Positive

• Trevi Therapeutics, Inc. will attend the European Respiratory Society International Congress 2023 in Milan, Italy from September 9-13. They will also participate in the SVB Securities Biopharma Summit in Montecito, CA from September 20-22, and the Cantor Global Healthcare Conference in New York, NY from September 26-28. Jennifer Good, President and CEO, will give a corporate presentation on September 26th at 4:55 PM ET.

Negative

• None.

NEW HAVEN, Conn., Sept. 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following events in September.

European Respiratory Society (ERS) International Congress 2023
September 9-13, Milan, Italy

2023 SVB Securities Biopharma Summit
September 20-22, Montecito, CA

2023 Cantor Global Healthcare Conference 
September 26-28, New York, NY
Corporate Presentation: Tuesday, September 26^th, 4:55 PM ET
Presenter: Jennifer Good, President and CEO

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis. Haduvio is a dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally as well as peripherally in the lungs and has the potential for a synergistic anti-tussive effect to treat chronic cough.

The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant.

Parenteral nalbuphine is not scheduled by the US Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on Twitter and LinkedIn.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-september-events-301918186.html

SOURCE Trevi Therapeutics, Inc.

What events will Trevi Therapeutics attend in September?

Trevi Therapeutics will attend the European Respiratory Society International Congress 2023, the SVB Securities Biopharma Summit, and the Cantor Global Healthcare Conference in September.

Who will give a corporate presentation at the Cantor Global Healthcare Conference?

Jennifer Good, President and CEO of Trevi Therapeutics, will give a corporate presentation at the Cantor Global Healthcare Conference.